Total cholesterol and LDL cholesterol were reduced in all trials but there was evidence of heterogeneity of effects .
There was no evidence of any serious harm caused by statin prescription .
Evidence available to date showed that primary prevention with statins is likely to be cost-effective and may improve patient quality of life .
Recent findings from the Cholesterol Treatment Trialists study using individual patient data meta- analysis indicate that these benefits are similar in people at lower ( < 1 % per year ) risk of a major cardiovascular event .
AUTHORS ' CONCLUSIONS Reductions in all-cause mortality , major vascular events and revascularisations were found with no excess of adverse events among people without evidence of CVD treated with statins
BACKGROUND Reducing high blood cholesterol , a risk factor for cardiovascular disease ( CVD ) events in people with and without a past history of CVD is an important goal of pharmacotherapy .
Statins are the first-choice agents .
Previous review s of the effects of statins have highlighted their benefits in people with CVD .
The case for primary prevention was uncertain when the last version of this review was published ( 2011 ) and in light of new data an up date of this review is required .
OBJECTIVES To assess the effects , both harms and benefits , of statins in people with no history of CVD .
Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial.
OBJECTIVES We evaluated the efficacy of statin therapy in primary prevention among individuals with moderate chronic kidney disease ( CKD ) . BACKGROUND Whether patents with moderate CKD ( estimated glomerular filtration rate [ eGFR ] < 60 ml/min/1.73 m(2 ) ) benefit from statin therapy is uncertain , particularly among those without hyperlipidemia or known cardiovascular disease . METHODS Within the JUPITER ( Justification for the Use of statins in Prevention-an Intervention Trial Evaluating Rosuvastatin ) primary prevention trial of rosuvastatin 20 mg compared with placebo among men and women free of cardiovascular disease who had low-density lipoprotein cholesterol ( LDL-C ) < 130 mg/dl and high-sensitivity C-reactive protein ( hsCRP ) > or=2 mg/l , we performed a secondary analysis comparing cardiovascular and mortality outcomes among those with moderate CKD at study entry ( n = 3,267 ) with those with baseline eGFR > or=60 ml/min/1.73 m(2 ) ( n = 14,528 ) . Median follow-up was 1.9 years ( maximum 5 years ) . RESULTS Compared with those with eGFR > or=60 ml/min/1.73 m(2 ) , JUPITER participants with moderate CKD had higher vascular event rates ( hazard ratio [ HR ] : 1.54 , 95 % confidence interval [ CI ] : 1.23 to 1.92 , p = 0.0002 ) . Among those with moderate CKD , rosuvastatin was associated with a 45 % reduction in risk of myocardial infa rct ion , stroke , hospital stay for unstable angina , arterial revascularization , or confirmed cardiovascular death ( HR : 0.55 , 95 % CI : 0.38 to 0.82 , p = 0.002 ) and a 44 % reduction in all-cause mortality ( HR : 0.56 , 95 % CI : 0.37 to 0.85 , p = 0.005 ) . Median LDL-C and hsCRP reductions as well as side effect profiles associated with rosuvastatin were similar among those with and without CKD . Median eGFR at 12 months was marginally improved among those allocated to rosuvastatin as compared with placebo . CONCLUSIONS Rosuvastatin reduces first cardiovascular events and all-cause mortality among men and women with LDL-C < 130 mg/dl , elevated hsCRP , and concomitant evidence of moderate CKD . ( JUPITER-Crestor 20 mg Versus Placebo in Prevention of Cardiovascular [ CV ] Events ; NCT00239681 )
Total cholesterol and LDL cholesterol were reduced in all trials but there was evidence of heterogeneity of effects .
There was no evidence of any serious harm caused by statin prescription .
Evidence available to date showed that primary prevention with statins is likely to be cost-effective and may improve patient quality of life .
Recent findings from the Cholesterol Treatment Trialists study using individual patient data meta- analysis indicate that these benefits are similar in people at lower ( < 1 % per year ) risk of a major cardiovascular event .
AUTHORS ' CONCLUSIONS Reductions in all-cause mortality , major vascular events and revascularisations were found with no excess of adverse events among people without evidence of CVD treated with statins
BACKGROUND Reducing high blood cholesterol , a risk factor for cardiovascular disease ( CVD ) events in people with and without a past history of CVD is an important goal of pharmacotherapy .
Statins are the first-choice agents .
Previous review s of the effects of statins have highlighted their benefits in people with CVD .
The case for primary prevention was uncertain when the last version of this review was published ( 2011 ) and in light of new data an up date of this review is required .
OBJECTIVES To assess the effects , both harms and benefits , of statins in people with no history of CVD .